AstraZeneca : Très bon démarrage de l’année
>T1 supérieur aux attentes, 275 M$ de ventes COVID-19 au T1 - AZN publie un T1 supérieur aux attentes (+5.5% vs Cs sur les revenus, +10% vs Cs sur BPA).La croissance à changes constants s’établit à +11% en topline et +55% en bottom line. La marge opérationnelle progresse de 5 points de pourcentage. Les première ventes vaccin COVID-19 sont annoncées à 275 M$ sur le trimestre.Guidance maintenue… pour l’instant selon nous - AstraZeneca réitère sa gu...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.